Applicants seeking a European patent from a PCT application must enter the European phase before the EPO within 31 months from the filing date or, where priority is claimed, from the earliest priority date.
| Patent office | European Patent Office (EPO) |
|---|---|
| Entry deadline | 31 months from the filing date or, if priority is claimed, from the earliest priority date. |
| Language / translation | A translation must be supplied if the Euro-PCT application was not published in one of the EPO's official languages. |
| Representation | Applicants without the required EPO-state residence or principal place of business should confirm the EPC professional-representation requirements and ordinarily use a European patent attorney. |
| Portfolio question | The EPO route can centralize examination for protection that may later take effect across selected European states, but validation, unitary effect and post-grant strategy still require separate commercial decisions. |
This page separates current office procedure from filing strategy. Deadlines, fees and office requirements can change, so consequential filing decisions should be checked against the official sources listed below.
EPO guidance states that applicants wishing to obtain a European patent from a PCT application must satisfy the European-phase requirements within 31 months from the filing date or, where priority was claimed, from the earliest priority date. The 31-month period applies regardless of whether a demand for international preliminary examination was filed.
EPO guidance emphasizes that entry into the European phase is not a single procedural act. Applicants must complete the relevant requirements within the 31-month period, including document-basis choices, translation where necessary and the applicable fees.
If the Euro-PCT application was not published in one of the EPO's official languages, the applicant must supply the required translation. Translation planning should be coordinated with claim review because the European prosecution record will depend on the documents selected as the basis for processing.
The EPO Guidelines identify the filing fee, designation fee and other potential charges among the requirements for European-phase entry. Applications over the relevant page threshold can attract additional page fees. Applicants should verify the current EPO fee schedule when preparing the entry package.
European-phase strategy includes the request for examination and examination fee within the applicable procedural framework. The PCT international search can affect the search-related procedure and fees, but it does not replace substantive EPO examination.
A key advantage of the EPO route is centralized examination before one office rather than separate prosecution in every European country. That can simplify pre-grant management, but post-grant territorial choices remain important because the resulting right must take effect in the states relevant to the applicant.
A European patent can require state-specific validation depending on the intended territorial effect, while eligible patentees may also consider unitary effect under the Unified Patent Court system. The filing strategy should therefore anticipate the post-grant countries likely to matter rather than stopping at EPO grant.
Software, AI, biotech, medical and other technologies can face EPO-specific approaches to technical character, inventive step, added matter and claim amendments. Euro-PCT claim strategy should therefore be reviewed against EPO practice, even when the international-stage report was favorable.
The EPO route is strongest where several European markets are commercially important and centralized examination creates efficiency. Applicants should compare expected EPO prosecution cost, validation or unitary-patent strategy, translations, renewals and enforcement value against filing separately in a smaller number of European states.
A useful international patent decision should state the user need, the technical or procedural issue, the desired commercial outcome, the jurisdictions being considered and the evidence supporting the choice. Recording those inputs makes later national-phase, prosecution and renewal decisions easier to review. It also helps distinguish a genuine strategic reason for filing from a generic preference to obtain broad geographic coverage.
Deadlines, fees, translation rules, examination practice and filing requirements can change. When a decision depends on one of those facts, verify it against the current patent-office, WIPO or regional-system material linked from the relevant page. Secondary explanation is useful for organizing the problem, but the strongest operational workflow is claim or requirement, nearby primary source, interpretation and practical implication.
Country selection should consider customers, infrastructure, manufacturing, competitors, licensing opportunities, regulatory market access, evidence of infringement and lifecycle patent cost. A large economy is not automatically the best patent market for every invention. The filing map should follow the commercial and technical footprint of the invention and should be revisited before national phase, grant and major renewal costs.
Products and technical architectures can change while prosecution is pending. The portfolio should be reviewed as the invention moves from prototype to deployment so open applications continue to support the features that drive revenue, licensing or defensive value. Where the implementation has changed, claims can be adjusted only within the support available in the original disclosure, making a technically complete first filing especially important.
Source code, process parameters, internal heuristics, datasets, tuning methods and operational procedures can be difficult for competitors to observe. Patent protection can be stronger for technical functionality that is externally detectable, reproducible or commercially licensable. The protection plan should define which information must be disclosed to support patent rights and which advantages can remain confidential without weakening the application.
Before acting on this page, identify the exact decision it is meant to support, the official source that controls any procedural requirement, the technical or commercial evidence that justifies the chosen jurisdiction, and the next deadline or document required. A clear decision record should also state what would cause the strategy to change. This makes the research usable during later prosecution, national-phase selection, budgeting and portfolio review rather than leaving it as a static summary.
Before acting on this page, identify the exact decision it is meant to support, the official source that controls any procedural requirement, the technical or commercial evidence that justifies the chosen jurisdiction, and the next deadline or document required. A clear decision record should also state what would cause the strategy to change. This makes the research usable during later prosecution, national-phase selection, budgeting and portfolio review rather than leaving it as a static summary.
Before acting on this page, identify the exact decision it is meant to support, the official source that controls any procedural requirement, the technical or commercial evidence that justifies the chosen jurisdiction, and the next deadline or document required. A clear decision record should also state what would cause the strategy to change. This makes the research usable during later prosecution, national-phase selection, budgeting and portfolio review rather than leaving it as a static summary.
Use current official requirements together with market, technology, manufacturing, licensing, competitor and enforcement considerations before committing to long-term portfolio cost.
rd (at) patentbusinesslawyer (dot) com
